Helixmith Co. Ltd Cash Flow Conversion Efficiency
Helixmith Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Helixmith Co. Ltd (084990) has a cash flow conversion efficiency ratio of -0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.38 Billion ≈ $-938.56K USD) by net assets (₩138.26 Billion ≈ $93.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Helixmith Co. Ltd (2010–2025)
Cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. This chart illustrates how Helixmith Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 084990 share price today for real-time trading data and today's change.
Helixmith Co. Ltd Cash Flow Conversion Ratio Explained
Helixmith Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Helixmith Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Helixmith Co. Ltd ranked by their cash flow conversion efficiency. Also see Helixmith Co. Ltd (084990) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Swiss Steel Holding AG
SW:STLN
|
-0.244x |
|
Yuyu Pharma
KO:000220
|
0.006x |
|
Mono Next Public Company Limited
BK:MONO
|
0.696x |
|
Feerum S.A.
WAR:FEE
|
0.073x |
|
Incross Co. Ltd
KQ:216050
|
0.093x |
|
HLV LIMITED
NSE:HLVLTD
|
0.007x |
|
M2I Corporation
KQ:347890
|
0.021x |
|
IHQ Inc
KO:003560
|
0.072x |
Annual Cash Flow Conversion Efficiency for Helixmith Co. Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. Review Helixmith Co. Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩141.52 Billion ≈ $95.91 Million |
₩-6.90 Billion ≈ $-4.67 Million |
-0.049x | +58.59% |
| 2024-12-31 | ₩142.04 Billion ≈ $96.26 Million |
₩-16.72 Billion ≈ $-11.33 Million |
-0.118x | +30.11% |
| 2023-12-31 | ₩153.72 Billion ≈ $104.18 Million |
₩-25.89 Billion ≈ $-17.54 Million |
-0.168x | +10.38% |
| 2022-12-31 | ₩216.80 Billion ≈ $146.92 Million |
₩-40.74 Billion ≈ $-27.61 Million |
-0.188x | -10.96% |
| 2021-12-31 | ₩225.35 Billion ≈ $152.72 Million |
₩-38.16 Billion ≈ $-25.86 Million |
-0.169x | +2.54% |
| 2020-12-31 | ₩276.30 Billion ≈ $187.25 Million |
₩-48.01 Billion ≈ $-32.54 Million |
-0.174x | +17.25% |
| 2019-12-31 | ₩195.57 Billion ≈ $132.53 Million |
₩-41.07 Billion ≈ $-27.83 Million |
-0.210x | -108.92% |
| 2018-12-31 | ₩133.87 Billion ≈ $90.72 Million |
₩-13.46 Billion ≈ $-9.12 Million |
-0.101x | -538.11% |
| 2017-12-31 | ₩164.45 Billion ≈ $111.45 Million |
₩-2.59 Billion ≈ $-1.76 Million |
-0.016x | -9.76% |
| 2016-12-31 | ₩170.93 Billion ≈ $115.84 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.014x | -188.31% |
| 2015-12-31 | ₩67.20 Billion ≈ $45.54 Million |
₩1.09 Billion ≈ $740.06K |
0.016x | +9598.28% |
| 2013-12-31 | ₩66.97 Billion ≈ $45.38 Million |
₩11.22 Million ≈ $7.60K |
0.000x | +100.30% |
| 2012-12-31 | ₩64.45 Billion ≈ $43.68 Million |
₩-3.58 Billion ≈ $-2.43 Million |
-0.056x | -26.50% |
| 2011-12-31 | ₩49.78 Billion ≈ $33.74 Million |
₩-2.19 Billion ≈ $-1.48 Million |
-0.044x | +12.11% |
| 2010-12-31 | ₩52.72 Billion ≈ $35.73 Million |
₩-2.64 Billion ≈ $-1.79 Million |
-0.050x | -- |
About Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more